Selective degradation of BRD9 by a DCAF16-recruiting targeted glue: mode of action elucidation and in vivo proof of concept

Scott J Hughes,Wojciech J Stech,Colin T.R. Davies,David McGarry,Alicia Williams,Ivan del Barco Barrantes,Rebecca Harris,Dominic D.G. Owens,Alexander Fawcett,John Hellicar,Gregor P Meier,Andrew C Runcie,Liliana Greger,Martin O'Rourke,Ian Churcher,Martin Pass,Giles A Brown,Alessio Ciulli,Louise Kelly Modis,Andrea Testa

DOI: https://doi.org/10.1101/2024.12.31.630899

2025-01-02

Abstract:Prospective discovery of molecular glues degraders for a specific therapeutic target protein of interest is an emerging strategy in drug discovery. Modification of pre-existing ligands with fragments that can alter the protein surface can lead to the creation of novel compounds (targeted glues) able to induce neo-interactions between the target and an E3 ligase, resulting in targeted protein degradation. By screening a library of potential BRD9 targeted glue compounds, we have discovered a potent and selective, reversibly covalent BRD9 degrader, AMPTX-1. Co-immunoprecipitation-mass spectrometry experiments demonstrated that cell treatment with AMPTX-1 induces selective recruitment of BRD9 to the E3 ligase DCAF16. Degradation is dependent on the engagement of the surface Cys58 of DCAF16 and formation of a covalent adduct to DCAF16 is facilitated by the ternary complex formation with BRD9. BRD9 degradation is achieved in vivo after oral dosing, demonstrating that covalent recruitment of DCAF16 is a viable strategy for targeted protein degradation and can be achieved with drug-like, orally bioavailable compounds with promising in vivo activity.

Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a new type of molecular glue degrader capable of specifically degrading BRD9 protein and clarify its mechanism of action. Specifically, the researchers hope to discover compounds that can recruit E3 ubiquitin - ligase DCAF16 and form covalent bonds with it by chemically modifying existing BRD9 ligands, thereby achieving the selective degradation of BRD9.

### Research Background

BRD9 is a bromodomain - containing protein. As part of the non - canonical BAF (ncBAF) chromatin - remodeling complex, it plays an important role in various cancers. Traditional PROTACs (bifunctional small - molecule degraders) and molecular glue degraders have demonstrated the ability to effectively degrade BRD9, but no molecular glue degrader targeting BRD9 has been reported yet. Therefore, developing a new and efficient molecular glue degrader is of great significance.

### Research Methods

The researchers achieved this goal through the following steps:

1. **Compound Library Screening**: By chemically modifying high - affinity BRD9 ligands, a potential targeted glue degrader library was constructed, and effective compounds were screened out through the HiBiT end - point degradation experiment.

2. **Activity Verification**: A highly efficient BRD9 degrader named AMPTX - 1 (DC50 = 0.05 nM, Dmax = 88%) was identified. Further experiments showed that AMPTX - 1 forms a covalent bond with DCAF16 through its cyanoacrylamide moiety, thereby achieving the selective degradation of BRD9.

3. **Mechanism of Action Analysis**: Through a series of experiments (including immunoprecipitation - mass spectrometry, competition experiments, etc.), it was proved that AMPTX - 1 forms a ternary complex with BRD9 by recruiting the DCAF16 - DDB1 complex, and covalently binds depending on the Cys58 residue on DCAF16, and then induces the ubiquitination and degradation of BRD9.

4. **In Vivo Verification**: Through mouse model experiments with oral administration, it was confirmed that AMPTX - 1 can effectively degrade BRD9 in vivo and has good pharmacokinetic properties.

### Main Conclusions

- AMPTX - 1 is a highly efficient and selective BRD9 molecular glue degrader, which can achieve the selective degradation of BRD9 by recruiting DCAF16.
- This degradation process depends on the covalent bond formed between the Cys58 residue on DCAF16 and AMPTX - 1.
- AMPTX - 1 also shows a good degradation effect in vivo, providing theoretical basis and technical support for the development of new drugs.

Through these studies, the authors not only successfully developed a new BRD9 degrader, but also revealed the potential of DCAF16 as a new E3 ubiquitin - ligase in targeted protein degradation, providing new ideas for future drug development.